MedTrace Logo

NeutraSal Treatment for Xerostomia in OSAS Patients Using CPAP Therapy

NCT02107300 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-12-11

Study results available
· View outcomes & findings →

Summary

To assess whether the daily use of NeutraSal will prevent or reduce dry mouth in patients undergoing CPAP therapy for OSAS and improve CPAP compliance

Conditions

  • Xerostomia

Interventions

DRUG

NeutraSal

NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.

DRUG

Placebo Comparator

Placebo is a powder consisting of sodium chloride only; chosen to mimic NeutraSal

Sponsors & Collaborators

  • Invado Pharmaceuticals LLC

    collaborator INDUSTRY

  • Medical University of South Carolina

    lead OTHER

Principal Investigators

  • Chitra Lal, MD · Medical University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2015-04-10
Completion
2017-07-03

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02107300 on ClinicalTrials.gov